NovaDel Announces Termination of Oral Spray License Agreements

News Jan 23, 2012

The company has announced the termination of certain license agreements with Talon Therapeutics, Inc. and Par Pharmaceutical Companies, Inc., relating to the development and commercialization of the Company's ondansetron HCl oral spray product.

Pursuant to the agreements terminating the Talon and Par license agreements, all rights to develop and commercialize the product were returned to the Company in exchange for Talon's right to receive certain royalty payments in connection with the product. The Company believes the termination of these license agreements better positions the Company for a potential strategic transaction by returning control of the product within the United States and Canada to the Company. Further details regarding the terms of the termination agreements can be found in the Company's Current Report on Form 8-K filed in connection herewith.

Human Gene Linked to a Better Recovery From Stroke

News

Neuroscientists have found that patients born without a gene called CCR5 recover better from mild stroke than patients with the gene.

Novel Therapeutic Approach to Treat Osteoarthritis

News

Researchers from Texas A&M University, led by Dr. Akhilesh K. Gaharwar, have developed a new way to deliver treatment for cartilage regeneration.

Machine Learning Swiftly Analyzes Nanomedicines for Cancer Immunotherapy

News

With their ability to treat a wide a variety of diseases, spherical nucleic acids are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A team has developed a direct route to optimize these particles, bringing them one step closer to becoming a viable treatment option for numerous diseases, including cancer.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free